Small molecule drug discovery for Dengue and West Nile viruses: Applying experience from hepatitis C virus

Future Medicinal Chemistry

Volumn 2, Issue 7, 2010, Pages 1181-1203

  Parkinson, Tanya ^a   Pryde, David C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANA 598; ANTIVIRUS AGENT; AURINTRICARBOXYLIC ACID; BIT 300; BMS 790052; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; FILIBUVIR; GS 9190; GS 9256; HELICASE; METHYLTRANSFERASE; N [[[6 (2 CARBOXY 2,3 DIHYDRO 1H ISOINDOL 4 YL) 2,2 DIMETHYLHEXYL]OXY]CARBONYL] 3 METHYLVALYL 4 HYDROXYPROLYL 1 AMINO N (CYCLOPROPYLSULFONYL) 2 ETHYLCYCLOPROPANECARBOXAMIDE LACTONE; NITD 008; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; POLYPROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RG 7128; RG 7227; RIBAVIRIN; TARIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 222; VX 759; VX 813; VX 985;

CLINICAL TRIAL; DENGUE VIRUS; DRUG PROGRAM; HEPATITIS C VIRUS; HUMAN; IC 50; NONHUMAN; NUCLEOTIDE METABOLISM; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA REPLICATION; VIRUS ENTRY; VIRUS ENVELOPE; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DRUG DISCOVERY; HEPACIVIRUS; HUMANS; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES; WEST NILE FEVER; WEST NILE VIRUS;

EID: 77954706293     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.195     Document Type: Review

References (155)

1. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. Fields Virology (5th Edition), 1101-1152 (2007).
2. Nash D, Mostashari F, Fine A et al. The outbreak of West Nile virus infection in the New York city area in 1999. N. Engl. J. Med. 344(24), 1807-1814 (2001).
3. Zeller HG, Schuffenecker I. West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur. J. Clin. Microbiol. Infect. Dis. 23(3), 147-156 (2004).
4. Granwehr BP, Lillibridge KM, Higgs S et al. West Nile virus: where are we now? Lancet Infect. Dis. 4(9), 547-556 (2004).
5. King NJC, Getts DR, Getts MT, Rana S, Shrestha B, Kesson AM. Immunopathology of flavivirus infections. Immunol. Cell Biol. 85(1), 33-42 (2007).
6. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421-467 (2003).
7. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225, 300-313 (2008).
8. Dauphin G, Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25(30), 5563-5576 (2007).
9. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis. 9(11), 678-687 (2009).
10. Rajapakse S. Intravenous immunoglobulins in the treatment of dengue illness. Trans. R. Soc. Trop. Med. Hyg. 103(9), 867-870 (2009).
11. Ghosh D, Basu A. Present perspectives on flaviviral chemotherapy. DrugDiscov. Today 13(13/14), 619-624 (2008).
12. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 427(6972), 313-319 (2004).
13. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH. Crystal structure of the West Nile virus envelope glycoprotein.J. Virol. 80(23), 11467-11474 (2006).
14. Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion.J. Virol. 83(9), 4338-4344 (2009).
15. 3 integrin. J. Biol. Chem. 281(3), 1352-1360 (2006).
16. Navarro-Sanchez E, Altmeyer R, Amara A et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4(7), 723-728 (2003).
17. Tassaneetrithep B, Burgess TH, Granelli-Piperno A et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197(7), 823-829 (2003).
18. Martina BEE, Koraka P, van den Doel P, Rimmelzwaan GF, Haagmans BL, Osterhaus ADME. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-α. Virus Res. 135(1), 64-71 (2008).
19. Miller JL, de Wet BJM, Martinez-Pomares L et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4(2), e17 (2008).
20. Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3(8), 866-871 (1997).
21. Chu JJ-h, Ng M-L. Interaction of West Nile virus with a integrin mediates virus entry into cells. J. Biol. Chem. 279(52), 54533-54541 (2004).
22. Krishnan MN, Sukumaran B, Pal U et al. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J. Virol. 81(9), 4881-4885 (2007).
23. Sabahi A. Hepatitis C virus entry: the early steps in the viral replication cycle. Virol. J. 6, 117 (2009).
24. Daughaday CC, Brandt WE, McCown JM, Russell PK. Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect. Immun. 32(2), 469-473 (1981).
25. Rodrigo WWSI, Jin X, Blackley SD, Rose RC, Schlesinger Jacob J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human FcgRIA (CD64) or FcgRIIA (CD32). J. Virol. 80(20), 10128-10138 (2006).
26. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J. Virol. 80(23), 11571-11578 (2006).
27. Wang Q-Y, Patel SJ, Vangrevelinghe E et al. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 53(5), 1823-1831 (2009).
28. Zhou Z, Khaliq M, Suk J-E et al. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem. Biol. 3(12), 765-775 (2008).
29. Li Z, Khaliq M, Zhou Z, Post CB, Kuhn RJ, Cushman M. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J. Med. Chem. 51(15), 4660-4671 (2008).
30. Yennamalli R, Subbarao N, Kampmann T, McGeary RP, Young PR, Kobe B. Identification of novel target sites and an inhibitor of the dengue virus E protein. J. Computer Aid. Mol. Design 23(6), 333-341 (2008).
31. Rees CR, Costin JM, Fink RC et al. In vitro inhibition of dengue virus entry by p-sulfoxy-cinnamic acid and structurally related combinatorial chemistries. Antiviral Res. 80(2), 135-142 (2008).
32. Marks RM, Lu H, Sundaresan R et al. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J. Med. Chem. 44(13), 2178-2187 (2001).
33. Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 69(1), 31-38 (2006).
34. Ono L, Wollinger W, Rocco IM, Coimbra TLM, Gorin PAJ, Sierakowski M-R. In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antiviral Res. 60(3), 201-208 (2003).
35. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363(2), 473-485 (2007).
36. Bielefeldt-Ohmann H, Meyer M, Fitzpatrick DR, Mackenzie JS. Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res. 73(1), 81-89 (2001).
37. Thepparit C, Smith DR. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J. Virol. 78(22), 12647-12656 (2004).
38. Balsitis SJ, Williams KL, Lachica R et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6(2), e1000790 (2010).
39. Eren R, Landstein D, Terkieltaub D et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80(6), 2654-2664 (2006).
40. Farci P. Hepatitis C virus. The importance of viral heterogeneity. Clin. Liver Dis. 5(4), 895-916 (2001).
41. Falgout B, Pethel M, Zhang YM, Lai CJ. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65(5), 2467-2475 (1991).
42. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67(5), 2832-2843 (1993).
43. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc. Natl Acad. Sci. USA. 90(22), 10583-10587 (1993).
44. Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R. Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob. Agents Chemother. 52(9), 3385-3393 (2008).
45. Ganesh VK, Muller N, Judge K, Luan C-H, Padmanabhan R, Murthy KHM. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13(1), 257-264 (2005).
46. Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L), towards dengue-2 virus NS3 protease. Bioorg. Med. Chem. Lett. 16(12), 3337-3340 (2006).
47. Erbel P, Schiering N, D'Arcy A et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13(4), 372-373 (2006).
48. Chappell KJ, Stoermer MJ, Fairlie DP, Young PR. West Nile Virus NS2B/NS3 protease as an antiviral target. Curr. Med. Chem. 15, 2771-2784 (2008).
49. Chappell KJ, Nall TA, Stoermer MJ et al. Site-directed mutagenesis and kinetic studies of the West Nile virus NS3 protease identify key enzyme-substrate interactions. J. Biol. Chem. 280(4), 2896-2903 (2005).
50. Li J, Lim SP, Beer D et al. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 280(31), 28766-28774 (2005).
51. Nall TA, Chappell KJ, Stoermer MJ et al. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J. Biol. Chem. 279(47), 48535-48542 (2004).
52. Yin Z, Patel SJ, Wang W-L et al. Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett. 16(1), 36-39 (2006).
53. Yin Z, Patel SJ, Wang W-L et al. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16(1), 40-43 (2006). (Pubitemid 41625637)
54. Stoermer MJ, Chappell KJ, Liebscher S et al. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J. Med. Chem. 51(18), 5714-5721 (2008).
55. Shiryaev SA, Ratnikov BI, Chekanov AV et al. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem. J. 393(2), 503-511 (2006).
56. Chanprapaph S, Saparpakorn P, Sangma C et al. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Comm. 330(4), 1237-1246 (2005).
57. Knox JE, Ma NL, Yin Z et al. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J. Med. Chem. 49(22), 6585-6590 (2006). (Pubitemid 44657452)
58. Murthy HMK, Judge K, DeLucas L, Padmanabhan R. Retracted: crystal structure of dengue virus NS3 protease in complex with a bowman-birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301(4), 759-767 (2000).
59. Shiryaev SA, Kozlov IA, Ratnikov BI, Smith JW, Lebl M, Strongin AY. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of dengue and West Nile viruses. Biochem. J. 401(3), 743-752 (2007).
60. Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang Y-P, Watowich SJ. Structure-based discovery of dengue virus protease inhibitors. Antivir. Res. 82(3), 110-114 (2009).
61. Johnston PA, Phillips J, Shun TY et al. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev. Technol. 5(6), 737-750 (2007).
62. Sidique S, Shiryaev SA, Ratnikov BI et al. Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile virus NS2B-NS3 proteinase. Bioorg. Med. Chem. Lett. 19(19), 5773-5777 (2009).
63. Su X-C, Ozawa K, Yagi H et al. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease. FEBS J. 276(15), 4244-4255 (2009).
64. Ekonomiuk D, Su X-C, Ozawa K et al. Discovery of a non-peptidic inhibitor of West Nile virus NS3 protease by high-throughput docking. PLoS Negl. Trop. Dis. 3(1), e356 (2009).
65. Thompson AJV, McHutchison JG. Review article: investigational agents for chronic hepatitis C. Aliment. Pharmacol. Ther. 29(7), 689-705 (2009).
66. Aleshin AE, Shiryaev SA, Strongin AY, Liddington RC. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci. 16(5), 795-806 (2007).
67. Tsantrizos YS. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Acc. Chem. Res. 41(10), 1252-1263 (2008).
68. Luo D, Xu T, Watson RP et al. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J. 27(23), 3209-3219 (2008).
69. Ujjinamatada RK, Baier A, Borowski P, Hosmane RS. An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2- yl)imidazole-1-[p]-D-ribofuranoside. Bioorg. Med. Chem. Lett. 1 7(8), 2285-2288 (2007).
70. Borowski P, Lang M, Haag A et al. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: Evidence for activity on the level of substrate and/or enzyme. Antimicrob. Agents Chemother. 46(5), 1231-1239 (2002).
71. Borowski P, Deinert J, Schalinski, S et al. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. 270(8), 1645-1653 (2003).
72. Zhang N, Chen H-M, Koch V et al.Ring-expanded nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J. Med. Chem. 46(19), 4149-4164 (2003).
73. Bretner M, Baier A, Kopanska K et al. Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues - inhibitors of the NTPase/ helicase of HCV and of some related Flaviviridae. Antivir. Chem. Chemother. 16(5), 315-326 (2005).
74. Olsen DB, Eldrup AB, Bartholomew L et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48(10), 3944-3953 (2004).
75. Yin Z, Chen Y-L, Schul W et al. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl Acad. Sci. USA. 106(48), 20435-20439 (2009).
76. Yin Z, Chen Y-L, Kondreddi RR et al. n-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase. J. Med. Chem. 52(24), 7934-7937 (2009).
77. Holler TP, Parkinson T, Pryde DC. Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase. Expert Opin. Drug Discov. 4(3), 293-314 (2009).
78. Beaulieu PL. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin. Ther. Pat. 19(2), 145-164 (2009).
79. Choi KH, Rossmann MG. RNA-dependent RNA polymerases from Flaviviridae. Curr. Opin. Struct. Biol. 19(6), 746-751 (2009).
80. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin. Investig. Drugs 18(6), 709-725 (2009).
81. Dong H, Ren S, Zhang B et al. West Nile virus methyltransferase catalyzes two methylations of the viral RNA cap through a substrate-repositioning mechanism. J. Virol. 82(9), 4295-4307 (2008).
82. Geiss BJ, Thompson AA, Andrews AJ et al. Analysis of flavivirus NS5 methyltransferase cap binding. J. Mol. Biol. 385(5), 1643-1654 (2009).
83. Zhou Y, Ray D, Zhao Y et al. Structure and function of flavivirus NS5 methyltransferase. J. Virol. 81(8), 3891-3903 (2007).
84. Luzhkov VB, Selisko B, Nordqvist A et al. Virtual screening and bioassay study of novel inhibitors for dengue virus mRNA cap (nucleoside-2'O)- methyltransferase. Bioorg. Med. Chem. 15(24), 7795-7802 (2007).
85. Milani M, Mastrangelo E, Bollati M et al. Flaviviral methyltransferase/ RNA interaction: structural basis for enzyme inhibition. Antiviral Res. 83(1), 28-34 (2009).
86. Hellebrekers DMEI, van Engeland M. Clinical trials and approved drugs for epigenetic cancer therapy. Cancer Epigenet. 415-425 (2009).
87. Dai Z, Kosuri K, Otterson GA. Mechanisms of DNA demethylating drugs against cancer progression. In: Cancer Metastasis \emdash Biology and Treatment. 243-267 (2005).
88. Sidwell RW, Huffman JH, Khare LGP, Allen B, Witkowski RJT, Robins K. Broad-spectrum antiviral activity of virazole: 1-f8- d-ribofuranosyl-1,2,4- triazole-3-carboxamide. Science 177(4050), 705-706 (1972).
89. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30(2), 201-205 (1986).
90. Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79(3), 1943-1947 (2005).
91. Morrey JD. Effect of interferon-a and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir. Chem. Chemother. 15, 101-109 (2004).
92. Chowers MY, Lang R, Nassar F et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerging Infect. Dis. 7(4), 675-678 (2001).
93. Koff WC, Pratt RD, Elm JL Jr, Venkateshan CN, Halstead SB. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob. Agents Chemother. 24(1), 134-136 (1983).
94. Lin C-C, Yeh L-T, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir. Chem. Chemother. 14(3), 145-152 (2003).
95. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 58(1), 73-79 (2003).
96. Ojwang JO, Ali S, Smee DF, Morrey JD, Shimasaki CD, Sidwell RW. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res. 68(2), 49-55 (2005).
97. Takhampunya R, Ubol S, Houng H-S, Cameron CE, Padmanabhan R. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87(7), 1947-1952 (2006).
98. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol. 36(4), 315-324 (1996).
99. Leyssen P, Van Lommel A, Drosten C, Schmitz H, De Clercq E, Neyts J. A novel model for the study of the therapy of flavivirus infections using the modoc virus. Virology 279(1), 27-37 (2001).
100. Diamond MS, Zachariah M, Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304(2), 211-221 (2002).
101. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 55(1), 107-116 (2002).
102. Sepulveda CS, Fascio ML, Mazzucco MB et al. Synthesis and evaluation of N-substituted acridones as antiviral agents against haemorrhagic fever viruses. Antiviral Chem. Chemother. 19(1), 41-47 (2008).
103. Nair V, Chi G, Shu Q, Julander J, Smee DF. A heterocyclic molecule with significant activity against dengue virus. Bioorg. Med. Chem. Lett. 19(5), 1425-1427 (2009).
104. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44(4), 859-866 (2000).
105. Bisceglie AMD, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123(12), 897-903 (1995).
106. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 351(9096), 83-87 (1998).
107. Cornberg M, Hinrichsen H, Teuber G et al. Mycophenolate mofetil in combination with recombinant interferon a-2a in interferon-nonresponder patients with chronic hepatitis C. J. Hepatol. 37(6), 843-847 (2002).
108. Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon a-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon a-2b plus ribavirin: a pilot study of efficacy and safety. Dig. Dis. Sci. 50(4), 719-726 (2005).
109. McHutchison JG, Shiffman ML, Cheung RC et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-a in previously untreated patients with chronic hepatitis C. Antiviral Ther. 10(5), 635-643 (2005).
110. Rustgi VK, Lee WM, Lawitz E et al. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology (Hoboken, NJ, USA), 50(6), 1719-1726 (2009).
111. Marcellin P, Gish RG, Gitlin N et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J. Hepatol. 52(1), 32-38 (2010).
112. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310(2), 333-342 (2003).
113. Malinoski FJ, Hasty SE, Ussery MA, Dalrymple JM. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 13(3), 139-149 (1990).
114. Samuel MA, Diamond MS. a/p interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79(21), 13350-13361 (2005).
115. Wu S-F, Lee C-J, Liao C-L, Dwek RA, Zitzmann N, Lin Y-L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76(8), 3596-3604 (2002).
116. Chang J, Wang L, Ma D et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 53(4), 1501-1508 (2009).
117. Whitby K, Pierson TC, Geiss B et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79(14), 8698-8706 (2005).
118. Liang P-H, Cheng W-C, Lee Y-L et al. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis. ChemBioChem 7(1), 165-173 (2006).
119. Chu JJH, Yang PL. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl Acad. Sci. USA. 104(9), 3520-3525 (2007).
120. Michaelis M, Kleinschmidt MC, Doerr HW, Cinatl J Jr. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J. Antimicrob. Chemother. 60(5), 981-986 (2007).
121. Mizutani T, Kobayashi M, Eshita Y et al. Involvement of the JNK-like protein of the Aedes albopictus mosquito cell line, C6/36, in phagocytosis, endocytosis and infection of West Nile virus. Insect Mol. Biol. 12(5), 491-499 (2003).
122. Durantel D. Celgosivir, an a-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs, 10(8), 860-870 (2009).
123. Kaita K YE, Kunimoto D, Anderson F et al. Phase II Study of Celgosivir in combination with peginterferon a-2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients. American Association for the Study of Liver Disease (AASLD) Abstracts. Abstract number 442. Gastroenterology, 132(4, Suppl. 2), A740 (2007).
124. Flisiak R, Dumont J-M, Crabbe R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin. Investig. Drugs 16(9), 1345-1354 (2007).
125. Li Q, Brass AL, Ng A et al. A genome-wide genetic-screen for host factors required for hepatitis C virus propagation. Proc. Natl Acad. Sci. USA 106(38), 16410-16415 (2009).
126. Ng TI, Mo H, Pilot-Matias T et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology, 45(6), 1413-1421 (2007).
127. Randall G, Panis M, Cooper JD et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104(31), 12884-12889 (2007).
128. Supekova L, Supek F, Lee J et al. Identification of human kinases involved in Hepatitis C virus replication by small interference RNA library screening. J. Biol. Chem. 283(1), 29-36 (2008).
129. Tai AW, Benita Y, Peng LF et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5(3), 298-307 (2009).
130. Vaillancourt FH, Pilote L, Cartier M et al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 387(1), 5-10 (2009).
131. Puig-Basagoiti F, Tilgner M, Forshey BM et al. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50(4), 1320-1329 (2006).
132. Noueiry AO, Olivo PD, Slomczynska U et al. Identification of novel small-molecule inhibitors of West Nile virus infection. J. Virol. 81(21), 11992-12004 (2007).
133. Barklis E, Still A, Sabri MI et al. Sultam Thiourea inhibition of West Nile virus. Antimicrob. Agents Chemother. 51(7), 2642-2645 (2007).
134. Zhang XG, Mason PW, Dubovi EJ et al. Antiviral activity of geneticin against dengue virus. Antiviral Res. 83(1), 21-27 (2009).
135. Puig-Basagoiti F, Qing M, Dong H et al. Identification and characterization of inhibitors of West Nile virus. Antiviral Res. 83(1), 71-79 (2009).
136. Rossi SL, Zhao Q, O'Donnell VK, Mason PW. Adaptation of West Nile virus replicons to cells in culture and use of replicon-bearing cells to probe antiviral action. Virology 331(2), 457-470 (2005).
137. Gu B, Ouzunov S, Wang L et al. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res. 70(2), 39-50 (2006).
138. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6(11), 881-890 (2007).
139. Kneteman NM, Howe AYM, Gao T et al. HCCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49(3), 745-752 (2009).
140. Shi ST, Herlihy KJ, Graham JP et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53(6), 2544-2552 (2009).
141. Tedesco R, Shaw AN, Bambal R et al. 3-(1,1-dioxo-2H-(1,2,4)- benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 49(3), 971-983 (2006).
142. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. DrugDeliv. Rev. 23(1-3), 3-25 (1997).
143. Biotron Ltd: WO2006135978 (2006).
144. Biotron Ltd: WO2004112687 (2004).
145. Novartis AG: WO2008095993 (2008).
146. Southern Research Institute: WO2008067002 (2008).
147. ZymeTx: US20060035848 (2006).
148. MNL Pharma Ltd: WO2007010266 (2007).
149. Institute of molecular and cell biology: WO200124785 (2001).
150. University of Pennsylvania: WO2008060695 (2008).
151. Siga Technologies: WO2008147962 (2008).
152. Apath LLC: WO2006121767 (2006).
153. University of Minnesota: WO2007038425 (2007).
154. Apath LLC: WO2006093518 (2006).
155. World Health Organisation www.who.int/csr/disease/dengue/impact/en/index. html. Itherex www.itherx.com/hepatitis.html